Justin Zelin
Stock Analyst at BTIG
(1.74)
# 3,774
Out of 5,182 analysts
40
Total ratings
31.71%
Success rate
-8.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Maintains: Buy | $6 → $9 | $7.70 | +16.88% | 2 | Jan 23, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $45 | $29.64 | +51.82% | 1 | Dec 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $24.23 | +131.12% | 5 | Dec 9, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $27.40 | +82.48% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $1.19 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.66 | +381.93% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $33.91 | +82.84% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.57 | +1,293.73% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $35.20 | +255.11% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $1.02 | +586.27% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $6.58 | +203.95% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $48.11 | -12.70% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.77 | +103,796.10% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $31.45 | +189.35% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $160 | $8.22 | +1,846.47% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.18 | +633.94% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $21.17 | +325.13% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $9.68 | +220.25% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $40.52 | -61.75% | 1 | Mar 28, 2023 |
ImmunityBio
Jan 23, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $7.70
Upside: +16.88%
ArriVent BioPharma
Dec 10, 2025
Initiates: Buy
Price Target: $45
Current: $29.64
Upside: +51.82%
Syndax Pharmaceuticals
Dec 9, 2025
Reiterates: Buy
Price Target: $56
Current: $24.23
Upside: +131.12%
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $27.40
Upside: +82.48%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.66
Upside: +381.93%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $33.91
Upside: +82.84%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.57
Upside: +1,293.73%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $35.20
Upside: +255.11%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $1.02
Upside: +586.27%
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $6.58
Upside: +203.95%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $48.11
Upside: -12.70%
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.77
Upside: +103,796.10%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $31.45
Upside: +189.35%
Aug 10, 2023
Maintains: Buy
Price Target: $320 → $160
Current: $8.22
Upside: +1,846.47%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.18
Upside: +633.94%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $21.17
Upside: +325.13%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $9.68
Upside: +220.25%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $40.52
Upside: -61.75%